Equity

BMED

iShares Health Innovation Active ETF

Add to Compare
  • NAV as of 28/Mar/2025 USD 24.40
    52 WK: 24.03 - 27.00
  • 1 Day NAV Change as of 28/Mar/2025 -0.16 (-0.67%)
  • NAV Total Return as of 27/Mar/2025 YTD: -1.60%
  • Morningstar Rating
  • Fees as stated in the prospectus Expense Ratio: 0.85%

Overview

Important Information: Capital at Risk. The value of investments and the income from them can fall as well as rise and are not guaranteed. Investors may not get back the amount originally invested.

Loading

Performance

Performance

Chart

View full chart
Chart
Line chart with 1131 data points.
The chart has 1 X axis displaying Time. Range: 2020-09-29 00:00:00 to 2025-03-28 00:00:00.
The chart has 1 Y axis displaying values. Range: -25 to 50.
YTD6M1Y3Y5Y10YAll
End of interactive chart.

The figures shown relate to past performance. Past performance is not a reliable indicator of future results and should not be the sole factor of consideration when selecting a product or strategy.

Share Class and Benchmark performance displayed in USD, hedged fund benchmark performance is displayed in USD.

Performance is shown on a Net Asset Value (NAV) basis, with gross income reinvested where applicable. Performance data is based on the net asset value (NAV) of the ETF which may not be the same as the market price of the ETF. Individual shareholders may realize returns that are different to the NAV performance.

The return of your investment may increase or decrease as a result of currency fluctuations if your investment is made in a currency other than that used in the past performance calculation. Source: Blackrock

Distributions

View full table

This chart shows the product's performance as the percentage loss or gain per year over the last 4 years.

Chart
Bar chart with 5 bars.
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying Values. Range: -25 to 10.
End of interactive chart.
  2020 2021 2022 2023 2024
Total Return (%) -4.0 -19.5 5.7 1.8
  1y 3y 5y 10y Incept.
Total Return (%) 1.81 -4.69 - - -0.15
  YTD 1m 3m 6m 1y 3y 5y 10y Incept.
Total Return (%) 1.81 -4.76 -4.73 -0.34 1.81 -13.42 - - -0.63

Key Facts

Key Facts

Net Assets of Fund
as of 28/Mar/2025
USD 2’928’085
Exchange
NYSE Arca
Distribution Frequency
Semi-Annual
CUSIP
09290C400
Fund Launch Date
29/Sept/2020
Asset Class
Equity
Premium/Discount
as of 28/Mar/2025
-0.04%
Volume - 1d
as of 28/Mar/2025
246.00

Portfolio Characteristics

Portfolio Characteristics

Number of Holdings
as of 28/Mar/2025
114
12 Month Trailing Dividend Distribution Yield
as of 28/Feb/2025
0.00%
Equity Beta (3y)
as of 28/Feb/2025
0.80
Standard Deviation (3y)
as of 28/Feb/2025
16.29%

Fees

Fees

as of current prospectus
Management Fee 0.85
Acquired Fund Fees and Expenses 0.00
Foreign Taxes and Other Expenses 0.00
Gross Expense Ratio 0.85

Ratings

Morningstar Rating

3 stars
Overall Morningstar Rating for iShares Health Innovation Active ETF, , as of 28/Feb/2025 rated against 165 Health Funds.

Morningstar Medalist Rating

Morningstar Medalist Rating - BRONZE
Morningstar has awarded the Fund a Bronze medal. (Effective 28/Feb/2025)
Analyst-Driven % as of 28/Feb/2025
55.00
Data Coverage % as of 28/Feb/2025
88.00

Registered Locations

Registered Locations

Holdings

Holdings

Download Holdings
Detailed Holdings and Analytics contains detailed portfolio holdings information and select analytics.



The values shown for “market value,” “weight,” and “notional value” (the “calculated values”) are based off of a price provided by a third-party pricing vendor for the portfolio holding and do not reflect the impact of systematic fair valuation (“the vendor price”). The vendor price is not necessarily the price at which the Fund values the portfolio holding for the purposes of determining its net asset value (the “valuation price”). Holdings data shown reflects the investment book of record, which may differ from the accounting book of record used for the purposes of determining the Net Assets of the Fund. Additionally, where applicable, foreign currency exchange rates with respect to the portfolio holdings denominated in non-U.S. currencies for the valuation price will be generally determined as of the close of business on the New York Stock Exchange, whereas for the vendor price will be generally determined as of 4 p.m. London. The calculated values may have been different if the valuation price were to have been used to calculate such values. The vendor price is as of the most recent date for which a price is available and may not necessarily be as of the date shown above.

Please see the “Determination of Net Asset Value” section of each Fund’s prospectus for additional information on the Fund’s valuation policies and procedures.

Exposure Breakdowns

Exposure Breakdowns

as of 28/Mar/2025

% of Market Value

as of 28/Mar/2025

% of Market Value

Geographic exposure relates principally to the domicile of the issuers of the securities held in the product, added together and then expressed as a percentage of the product’s total holdings. However, in some instances it can reflect the location where the issuer of the securities carries out much of their business.
Allocations are subject to change.

Listings

Listings

Portfolio Managers

Portfolio Managers

Erin Xie, PhD
Erin Xie, PhD

 

Erin Xie, PhD, Managing Director and portfolio manager, is the head of the Health Sciences team, part of BlackRock’s Active Equity Group. She is the lead portfolio manager for the Health Sciences equity portfolios.

Read More

Erin Xie, PhD, Managing Director and portfolio manager, is the head of the Health Sciences team, part of BlackRock’s Active Equity Group. She is the lead portfolio manager for the Health Sciences equity portfolios.

 

Ms. Xie's service with the firm dates back to 2001, including her years with State Street Research & Management (SSRM), which merged with BlackRock in 2005. At SSRM, she was a Senior Vice President and portfolio manager responsible for managing the State Street Health Sciences Fund. Prior to joining State Street Research in 2001, Ms. Xie was a research associate with Sanford Bernstein covering the pharmaceutical industry from 1999. From 1994 until 1997, she was a post doctoral research scientist at Columbia University.

 

Ms. Xie earned a BS degree in chemistry from Beijing University in 1988, a PhD degree in Biochemistry from the University of California, Los Angeles, in 1993 and a MBA degree from the Massachusetts Institute of Technology Sloan School of Management in 1999.

Xiang Liu, PhD
Xiang Liu, PhD

 

Xiang Liu, PhD, Managing Director and portfolio manager, is a member of the Health Sciences team, part of BlackRock’s Active Equity Group. He is co-portfolio manager for the Health Sciences equity portfolios and is responsible for coverage of the medical devices & supplies sector.

Read More

Xiang Liu, PhD, Managing Director and portfolio manager, is a member of the Health Sciences team, part of BlackRock’s Active Equity Group. He is co-portfolio manager for the Health Sciences equity portfolios and is responsible for coverage of the medical devices & supplies sector.

 

Prior to joining BlackRock in 2008, Mr. Liu was a partner and biotech analyst at Mehta Partners. From 2002 to 2005, he was a Director in the corporate development department at Cubist Pharmaceuticals. Mr. Liu began his investment career in 2000 at the Boston Consulting Group as a Healthcare consultant.

 

Mr. Liu earned a BS degree in Chemistry from the University of Science & Technology, China in 1993, a PhD degree in Chemistry from Yale University in 1997, and a MBA degree in finance, strategy, and accounting from the University of Chicago in 2000.

Literature

Literature

No documents available for this fund
See all documents